{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.77","value":"-0.8"},{"groupId":"OG001","spread":"14.35","value":"-6.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"52"}],"units":"Participants"}],"title":"Week 12 - CORE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.38","value":"-0.6"},{"groupId":"OG001","spread":"15.19","value":"-7.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"48"}],"units":"Participants"}],"title":"Week 24 - CORE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"54"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution) for intramuscular administration every 28 days","id":"OG000","title":"Pasireotide LAR 40 mg"},{"description":"Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution) for intramuscular administration every 28 days","id":"OG001","title":"Pasireotide LAR 60 mg"}],"paramType":"MEAN","populationDescription":"Number analyzed is based on available data at specific visits","reportingStatus":"POSTED","timeFrame":"CORE baseline up to approximately 24 weeks","title":"Change From Baseline in Mean GH Values for Patients Treated With Pasireotide LAR Alone or With Concomitant Medications Used to Treat Acromegaly for CORE Visits (Extension Full Analysis Set)","type":"SECONDARY","unitOfMeasure":"mcg/L"}